Based on the attached case details address the following in at least 1. External environment (threats and
Fantastic news! We've Found the answer you've been seeking!
Question:
Based on the attached case details address the following in at least
1. External environment (threats and opportunities)
2. Internal capabilities
3. Recommended business-level strategy to follow
Transcribed Image Text:
Case 2-5: Torrey Nano, Inc. processes could lead to failure. Moreover, i Jack Heiner, the CEO of Torrey Nano, a seven-year-old bio- technology firm, faced an important decision in the spring reported that firms often had difficulty transfen.m of 2017. Torrey Nano, based in San Diego, California was a facturing process from one facility to another. Few company of 35 employees, most of whom were research sci- entists. Torrey Nano's pharmaceutical product, codename Nano-4, was almost ready for human testing. The company aspired to be a full-fledged pharmaceutical company. How- involving nanotechnology. Even for these firms, though ever, like most biotech startups, it had focused on R&D since often required considerable trial and error before maste its founding. Consequently, it had done no manufacturing or marketing. With the impending human testing of Nano-4, however, it faced the decision of whether to build a small- scale pilot plant to manufacture Nano-4 for human trials. Nano-4 was the fourth product that Torrey Nano had devel- oped but the first to advance to human trials. The drug had multiple potential therapeutic applications, but Torrey Nano had focused on diabetes treatment as its first application. The company had three other products in earlier stages of development. Human testing involved three phases. Phase I, which lasted from 6-12 months, assessed basic human safety (e.g., adverse side effects, etc.). If a product was approved in Phase I, it moved to Phase II where the drug was tested with a small group of patients. Phase II examined the efficacy of a drug in treating a disease and also evaluated whether serious side effects occurred. Phase II usually lasted from one to two years. Products that succeeded in Phases I and II could go on to Phase III. Phase III, which could take two to five years to complete, tested the drug using a large sample tributed and marketed by an established pharmaceutical of patients. Regulations required that whatever manufac- turing processes were used in Phase III must be the same as those used after the drug was approved and marketed commercially. The manufacturing of drugs based on nanotechnol- ogy was considered highly complex and uncertain. Drugs Table 2). As Heiner contemplated his options, it was dear based on nanotechnology were particularly new in 2017 but that the scenarios involving in-house manufacturing wert were generally thought to hold great promise for a wide costlier, but potentially more lucrative. Both of the first tw variety of diseases. Several reports suggested that manu- facturing nano-materials was both difficult to replicate build a pilot plant while scenarios 1 and 3 required large and scale. Thus, it was challenging to develop effective capital outlays to build a full-scale plant in 2020 and 202 processes for manufacturing new nano-drugs. Some nano- technology drugs, while feasible to make in the small quan- ing a full-scale plant would allow Torrey Nano to captu tities needed for pilot studies, were especially problematic a higher percentage of the revenue stream for Nano-$ to manufacture on a large scale. Very small differences in companies had experience manufacturing products of type of Nano-4. There were, however, a handful of cont manufacturers who had some experience in manufacturi the process for a particular drug. Torrey Nano managers identified five possible scena jos for how they might handle the manufacturing of Nano The five scenarios are listed here with cash flow estimate included in Table 1. Scenario 1: Torrey Nano builds a pilot plant for Phae 1/1I and a full-scale plant for Phase III. Scenario 2: Torrey Nano builds a pilot plant for Phases 1/II and licenses out the manufacturing righ for Phase III. Scenario 3: Contract out manufacturing for Phases ! II, build a full-scale plant in-house for Phase II. Scenario 4: Contract out manufacturing for Phases II and license out manufacturing rights for Phase I. Scenario 5: Manufacturing in all phases would be done by licensee. In all five scenarios, Nano-4 would ultimately be dis firm that would serve as Torrey Nano's and/or the eventual manufacturer's, marketing partner. If Nano-4 successfully navigated clinical testing to reach the commercial stage, ana lysts projected sales ranging from $75 million in 2025 to over $288 million in 2035, the last year of patent protection (se scenarios required capital investments in 2018 and 2019 t0 (see Table 3). Cash flow projections suggested that build * This case is intended for class discussion only. Torrey Nano is a fictitious company and, while nanotechnology is believed to offer great promise for the future in pharmaceuticals, technical details in million licensing fee from its marketing partner in 20 upon successful completion of clinical trials and 40 percent of royalties. Licensing the manufacturing rights after Pha II, as required by Scenarios 2 and 4, would yield a lowe payout-$10 million licensing fee from the marketing pa nar and 10 norrvnt walties Case 2-5: Torrey Nano, Inc. 49 Table 1 Forecasted Cash Flows for Torrey Nano Investment Scenarios Phase 1II Torrey Nano Torrey Nano Contractor Contractor Licensee Phase III Torrey Nano Licensee Torrey Nano Licensee Licensee Year Scenario 1 Scenario 2 Scenario 3 Scenario 4 Scenario 5 2018 -5,000 -5,000 5,000 -3,000 -33,000 -3,000 -3,000 2019 -4,000 -4,000 2020 -34,500 -4,500 2021 2022 2023 2024 2025 45,000 17,500 45,000 17,500 3,750 2026 56,000 14,000 56,000 14,000 7,000 2027 70,000 17,500 70,000 17,500 8,750 2028 78,000 19,500 78,000 19,500 9,750 2029 86,000 21,500 86,000 21,500 10,750 2030 90,300 22,575 90,300 22,575 11,288 2031 94,815 23,704 94,815 23,704 11,852 2032 99,556 24,889 99,556 24,889 12,444 104,534 109,760 115,248 2033 104,534 26,133 26,133 13,067 2034 109,760 27,440 27,440 13,720 2035 115,248 28,812 28,812 14,406 A pilot plant with sufficient capacity to pro- duce output for Phases I and II involved a $5 million investment in 2018. This investment would cover all expenses including facilities and plant equipment. The company would still incur $1 million in production costs in 2019 and 2020 as well as $2 million in expenses for the clinicai trials in those years. A larger-scale plant for Phase III and commercialization would require a $30 mil- lion investment in 2020. Torrey Nano had sufficient funds for the Phase 1/11 investment. The Phase II investment Table 2 Projected Sales from Nano-4 (in 000's) 2025 $75,000 2026 $140,000 2027 $175,000 2028 $195,000 2029 $215,000 2030 $225,750 would require another round of venture capital fund- ing. Heiner and Torrey Nano's board, however, were convinced that such funding was highly likely if Nano-4 successfully completed Phase 1/Il testing. Venture capi- talists expected returns of 30%, which a successful phar- maceutical product would insure for a biotech firm such as Torrey Nano, 2031 $237,038 2032 $248,889 2033 $261,334 2034 $274,401 2035 $288,121 Case 2-5: Torrey Nano, Inc. processes could lead to failure. Moreover, i Jack Heiner, the CEO of Torrey Nano, a seven-year-old bio- technology firm, faced an important decision in the spring reported that firms often had difficulty transfen.m of 2017. Torrey Nano, based in San Diego, California was a facturing process from one facility to another. Few company of 35 employees, most of whom were research sci- entists. Torrey Nano's pharmaceutical product, codename Nano-4, was almost ready for human testing. The company aspired to be a full-fledged pharmaceutical company. How- involving nanotechnology. Even for these firms, though ever, like most biotech startups, it had focused on R&D since often required considerable trial and error before maste its founding. Consequently, it had done no manufacturing or marketing. With the impending human testing of Nano-4, however, it faced the decision of whether to build a small- scale pilot plant to manufacture Nano-4 for human trials. Nano-4 was the fourth product that Torrey Nano had devel- oped but the first to advance to human trials. The drug had multiple potential therapeutic applications, but Torrey Nano had focused on diabetes treatment as its first application. The company had three other products in earlier stages of development. Human testing involved three phases. Phase I, which lasted from 6-12 months, assessed basic human safety (e.g., adverse side effects, etc.). If a product was approved in Phase I, it moved to Phase II where the drug was tested with a small group of patients. Phase II examined the efficacy of a drug in treating a disease and also evaluated whether serious side effects occurred. Phase II usually lasted from one to two years. Products that succeeded in Phases I and II could go on to Phase III. Phase III, which could take two to five years to complete, tested the drug using a large sample tributed and marketed by an established pharmaceutical of patients. Regulations required that whatever manufac- turing processes were used in Phase III must be the same as those used after the drug was approved and marketed commercially. The manufacturing of drugs based on nanotechnol- ogy was considered highly complex and uncertain. Drugs Table 2). As Heiner contemplated his options, it was dear based on nanotechnology were particularly new in 2017 but that the scenarios involving in-house manufacturing wert were generally thought to hold great promise for a wide costlier, but potentially more lucrative. Both of the first tw variety of diseases. Several reports suggested that manu- facturing nano-materials was both difficult to replicate build a pilot plant while scenarios 1 and 3 required large and scale. Thus, it was challenging to develop effective capital outlays to build a full-scale plant in 2020 and 202 processes for manufacturing new nano-drugs. Some nano- technology drugs, while feasible to make in the small quan- ing a full-scale plant would allow Torrey Nano to captu tities needed for pilot studies, were especially problematic a higher percentage of the revenue stream for Nano-$ to manufacture on a large scale. Very small differences in companies had experience manufacturing products of type of Nano-4. There were, however, a handful of cont manufacturers who had some experience in manufacturi the process for a particular drug. Torrey Nano managers identified five possible scena jos for how they might handle the manufacturing of Nano The five scenarios are listed here with cash flow estimate included in Table 1. Scenario 1: Torrey Nano builds a pilot plant for Phae 1/1I and a full-scale plant for Phase III. Scenario 2: Torrey Nano builds a pilot plant for Phases 1/II and licenses out the manufacturing righ for Phase III. Scenario 3: Contract out manufacturing for Phases ! II, build a full-scale plant in-house for Phase II. Scenario 4: Contract out manufacturing for Phases II and license out manufacturing rights for Phase I. Scenario 5: Manufacturing in all phases would be done by licensee. In all five scenarios, Nano-4 would ultimately be dis firm that would serve as Torrey Nano's and/or the eventual manufacturer's, marketing partner. If Nano-4 successfully navigated clinical testing to reach the commercial stage, ana lysts projected sales ranging from $75 million in 2025 to over $288 million in 2035, the last year of patent protection (se scenarios required capital investments in 2018 and 2019 t0 (see Table 3). Cash flow projections suggested that build * This case is intended for class discussion only. Torrey Nano is a fictitious company and, while nanotechnology is believed to offer great promise for the future in pharmaceuticals, technical details in million licensing fee from its marketing partner in 20 upon successful completion of clinical trials and 40 percent of royalties. Licensing the manufacturing rights after Pha II, as required by Scenarios 2 and 4, would yield a lowe payout-$10 million licensing fee from the marketing pa nar and 10 norrvnt walties Case 2-5: Torrey Nano, Inc. 49 Table 1 Forecasted Cash Flows for Torrey Nano Investment Scenarios Phase 1II Torrey Nano Torrey Nano Contractor Contractor Licensee Phase III Torrey Nano Licensee Torrey Nano Licensee Licensee Year Scenario 1 Scenario 2 Scenario 3 Scenario 4 Scenario 5 2018 -5,000 -5,000 5,000 -3,000 -33,000 -3,000 -3,000 2019 -4,000 -4,000 2020 -34,500 -4,500 2021 2022 2023 2024 2025 45,000 17,500 45,000 17,500 3,750 2026 56,000 14,000 56,000 14,000 7,000 2027 70,000 17,500 70,000 17,500 8,750 2028 78,000 19,500 78,000 19,500 9,750 2029 86,000 21,500 86,000 21,500 10,750 2030 90,300 22,575 90,300 22,575 11,288 2031 94,815 23,704 94,815 23,704 11,852 2032 99,556 24,889 99,556 24,889 12,444 104,534 109,760 115,248 2033 104,534 26,133 26,133 13,067 2034 109,760 27,440 27,440 13,720 2035 115,248 28,812 28,812 14,406 A pilot plant with sufficient capacity to pro- duce output for Phases I and II involved a $5 million investment in 2018. This investment would cover all expenses including facilities and plant equipment. The company would still incur $1 million in production costs in 2019 and 2020 as well as $2 million in expenses for the clinicai trials in those years. A larger-scale plant for Phase III and commercialization would require a $30 mil- lion investment in 2020. Torrey Nano had sufficient funds for the Phase 1/11 investment. The Phase II investment Table 2 Projected Sales from Nano-4 (in 000's) 2025 $75,000 2026 $140,000 2027 $175,000 2028 $195,000 2029 $215,000 2030 $225,750 would require another round of venture capital fund- ing. Heiner and Torrey Nano's board, however, were convinced that such funding was highly likely if Nano-4 successfully completed Phase 1/Il testing. Venture capi- talists expected returns of 30%, which a successful phar- maceutical product would insure for a biotech firm such as Torrey Nano, 2031 $237,038 2032 $248,889 2033 $261,334 2034 $274,401 2035 $288,121
Expert Answer:
Answer rating: 100% (QA)
SWOT Analysis SWOT analysis is the best parameter to identify and evaluat... View the full answer
Posted Date:
Students also viewed these management leadership questions
-
Based on the attached job description, you are required to write a series of questions that you would use to interview candidates for this position. 1. Construct 2 Behavioural Based interview...
-
Based on the attached chart what challenges, if any, are presented in International Business based on religious differences. Since sixty-seven percent of the world population is not Christian, does...
-
Opportunities and threats have to do with external factors. What sources could be useful for obtaining this information?
-
Katz Hat Shop received a shipment of hats for which it paid the wholesaler $2,970. The price of the hats was $3,000, but Katz was given a $30 cash discount and required to pay freight charges of $50....
-
The mileage death rate for motorcycle riders has been estimated to be about 39 deaths per 100 million miles of motorcycle travel. A national motorcycling association has 1200 members who travel a...
-
The manufacturing operations of R Eason, Inc had the following balances for the month of January: Reason transferred $ 220000 of completed goods out of work in process during January. Instructions:...
-
Describe the accounting treatment for a forward exchange contract where there is no hedging relationship.
-
Given the following transactions engaged in by Stanford Company, prepare journal entries and, assuming the periodic inventory system, determine the total amount received from Penkas Company. Mar. 1...
-
The Power of Trade and Comparative Advantage: Work It Out 3 ? Here's another specialization and exchange problem. This problem is wholly made-up, ? so that you won't be able to use your intuition...
-
John has created an incredibly successful wine operation in the Northeast. All 5 are in a separate S-Corporation with all the stock owned by the parent Company Petosa Vineyards Inc, also an...
-
JDS Enterprises borrowed $150,000 on February 1, 2018 to purchase equipment. JDS signed a $150,000, 6%, 8-year promissory note. The loan requires that JDS pays an annual, blended interest payment of...
-
Read the following Why do you agree with James 1. Overfishing takes short-term self interest against the common good. It provides an opportunity for an individual to benefit oneself while spreading...
-
Penn Corp. is analyzing the possible acquisition of Teller Company. Both firms have no debt. Penn believes the acquisition will increase its total aftertax annual cash flow by $1.9 million...
-
Write up a general supply function for housing (specify the variables mentioned in this article that impact the supply side of the market-note-there are some variables mentioned that are not included...
-
https://act.pearsoncmg.com/activity/1/4/2 Beginning of Year: End of Year: Assets Liabilities $27,000 $18,000 $64,000 $26,000 1) What is the equity at the beginning of the year? Beginning Equity 9000...
-
Brandon Technology makes two models of a specialized sensor for the aerospace industry. The difference in the two models relates to the required accuracy of the sensor. The Standard model is used for...
-
A) Given The circuit shown is at equilibrium at t = 0- : 10V + B) Determine 2.50 0.4F Ic (t) + Vc(t) Step 1: The value of Vc(0-), Step 2: The value of Vc(), t=0 100 Step 3: The time constant T, Step...
-
Time Solutions, Inc. is an employment services firm that places both temporary and permanent workers with a variety of clients. Temporary placements account for 70% of Time Solutions' revenue;...
-
Name three or more branches of Earth science, and describe the focus of each.
-
Where is lithosphere created? Where is it destroyed?
-
What are the large, interlocking pieces of lithosphere called?
Study smarter with the SolutionInn App